Form: SC 13D/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

December 19, 2018

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

Each of the undersigned hereby agrees that this Amendment No. 10 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended.

 

Date: December 18, 2018

 

  Mayne Pharma Ventures Pty Ltd
   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary 

 

 

Mayne Pharma International Pty Ltd

 

   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary 

 

 

Mayne Pharma Group Limited

 

   
 

/s/ Nick Freeman

Nick Freeman, Company Secretary